[68Ga]Ga-FAPI Surpasses [18F]FDG in Pancreatic Adenosquamous Carcinoma Restaging.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 41632577.
- Also identified by DOI 10.1097/RLU.0000000000006284.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Pancreatic adenosquamous carcinoma (PASC) represents a rare, aggressive exocrine neoplasm. We describe a 33-year-old woman with an aggressive disease trajectory and limited survival. Baseline [18F]FDG PET/CT enabled accurate staging and treatment planning of stage IV malignancy. Following FOLFIRINOX chemotherapy, complete metabolic resolution was achieved on follow-up [18F]FDG PET/CT. Nevertheless, disease relapse ensued within 5 months. During restaging, [18F]FDG PET/CT failed to reveal any hypermetabolic lesions, whereas [68Ga]Ga-FAPI PET/CT successfully identified both local and metastatic recurrences. Notably, this case highlights the superiority of [68Ga]Ga-FAPI PET/CT for detecting recurrent PASC compared with [18F]FDG PET/CT.
Medical subject headings
- Fluorodeoxyglucose F18
- Carcinoma, Adenosquamous
- Pancreatic Neoplasms
- Positron Emission Tomography Computed Tomography
- Lipopeptides